Comparison of efficacy and safety of recombinant human brain natriuretic peptide in different courses on patients with acute heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069664

Enrollment

Unknown

Registered

2023-03-22

Start date

2022-02-18

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

test group:long course of treatment with recombinant human brain natriuretic peptide

control group:short course of treatment with recombinant human brain natriuretic peptide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >= 18 years old, meeting 2018 guidelines for the diagnosis and treatment of heart failure in China, NYHA cardiac function grade III-IV

Exclusion criteria

Exclusion criteria: SBP<=90mmHg (1mmHg = 0.133kPa); Cardiogenic shock; Insufficient blood volume; Contraindications to use of venous vasodilators; Severe valve stenosis; Hypertrophic or restrictive cardiomyopathy; Constrictive pericarditis; Pregnant woman

Design outcomes

Primary

Measure	Time frame
clinical situation;assessment of cardiac and renal functions;	—

Secondary

Measure	Time frame
security;	—

Countries

China

Contacts

Public ContactWei Wen

Beijing Hospital

wenwei7242@163.com13811830971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026